ABSTRACT
Subependymoma is a rare primary brain tumor, constituting 0.07-0.51% of brain tumors. Genetic alterations in subependymoma are largely unknown, but familial occurrences have been reported. Trichorhinophalangeal syndrome type 1 (TRPS1) is a rare hereditary malformation complex caused by mutations in a gene identified in the year 2000 on 8q24.12. We report two patients with TRPS I and surgically treated subependymomas, one of whom has a first degree relative, now deceased, who was affected and also had a subependymoma. We therefore sought a role for the TRPS1 gene in the molecular oncogenesis of subependymoma. Formalin fixed tumor specimens and saliva samples were obtained from the two index patients as well as tumor samples from six sporadic subependymoma surgical specimens. A heterozygous TRPS1 germ line mutation predicted to cause a frame shift leading to a premature stop codon was found in the first index patient and also present in the associated tumor. No germline mutation was found in the second index patient, but his tumor displayed copy number neutral loss of heterozygosity in TRPS1. TRPS1 mutation analysis of the sporadic subependymomas revealed genetic, mostly loss of function alterations in one-third (two of six) of samples. Genetic alterations in TRPS1 likely play a role in at least a subgroup of subependymomas. Confirmation and further (epi)genetic investigations, ideally in newly acquired, fresh-frozen tumor samples, are warranted.
Subject(s)
Brain Neoplasms/genetics , Brain Neoplasms/physiopathology , DNA-Binding Proteins/genetics , Glioma, Subependymal/genetics , Glioma, Subependymal/physiopathology , Mutation/genetics , Transcription Factors/genetics , Adult , DNA Mutational Analysis , Female , Humans , Male , Repressor ProteinsABSTRACT
Subependymoma was first described by Scheinker in 1945; it frequently occurs in the ventricles and rarely in the spinal canal representing 0.7% of all central nervous system tumours. Most of these intraventricular tumours are subclinical entities, remaining of small size and discovered at autopsy with 0.4%incidence. We report a case of subependymoma with a completely exophytic growth from the foramen of Luscka: only a similar one has been described in the literature but with a lesser cysternal involvement. Neuroradiological and anatomopathological features of subependymoma are discussed.
Subject(s)
Cerebellopontine Angle/pathology , Cerebral Ventricle Neoplasms/pathology , Fourth Ventricle/pathology , Glioma, Subependymal/pathology , Adult , Cerebellopontine Angle/physiopathology , Cerebellopontine Angle/surgery , Cerebral Ventricle Neoplasms/physiopathology , Cerebral Ventricle Neoplasms/surgery , Cranial Nerves/pathology , Cranial Nerves/surgery , Fourth Ventricle/physiopathology , Glioma, Subependymal/physiopathology , Glioma, Subependymal/surgery , Humans , Hydrocephalus/etiology , Hydrocephalus/physiopathology , Hydrocephalus/prevention & control , Magnetic Resonance Imaging , Male , Medulla Oblongata/pathology , Medulla Oblongata/surgery , Muscle Weakness/etiology , Nausea/etiology , Neurosurgical Procedures , Pons/pathology , Pons/surgery , Treatment OutcomeABSTRACT
BACKGROUND: Subependymal giant cell astrocytomas (SEGAs) are low-grade tumors affecting up to 20% of patients with tuberous sclerosis complex (TSC). Early neurosurgical resection has been the only standard treatment until few years ago when a better understanding of the molecular pathogenesis of TSC led to the use of mammalian target of rapamycin (mTOR) inhibitors. Surgical resection of SEGAs is still considered as the first line treatment in individuals with symptomatic hydrocephalus and intratumoral hemorrhage. We describe four patients with symptomatic or asymptomatic hydrocephalus who were successfully treated with the mTOR inhibitor everolimus. METHODS: We collected the clinical data of four consecutive patients presenting with symptomatic or asymptomatic hydrocephalus due to a growth of subependymal giant cell atrocytomas and who could not undergo surgery for different reasons. RESULTS: All patients experienced a clinically significant response to everolimus and an early shrinkage of the SEGA with improvement in ventricular dilatation. Everolimus was well tolerated by all individuals. CONCLUSIONS: Our clinical series demonstrate a possible expanding indication for mTOR inhibition in TSC, which can be considered in patients with asymptomatic hydrocephalus or even when the symptoms already appeared. It offers a significant therapeutic alternative to individuals that once would have undergone immediate surgery. Everolimus might also allow postponement of a neurosurgical resection, making it elective with an overall lower risk.
Subject(s)
Antineoplastic Agents/therapeutic use , Brain Neoplasms/drug therapy , Everolimus/therapeutic use , Glioma, Subependymal/drug therapy , Hydrocephalus/drug therapy , TOR Serine-Threonine Kinases/antagonists & inhibitors , Adolescent , Brain/diagnostic imaging , Brain/drug effects , Brain Neoplasms/complications , Brain Neoplasms/physiopathology , Female , Glioma, Subependymal/complications , Glioma, Subependymal/physiopathology , Humans , Hydrocephalus/etiology , Hydrocephalus/physiopathology , Male , Randomized Controlled Trials as Topic , TOR Serine-Threonine Kinases/metabolism , Tumor Burden , Young AdultABSTRACT
BACKGROUND: Subependymomas are uncommonly encountered ependymal tumors, which are important to distinguish from ordinary ependymomas because of their generally better prognosis. OBJECTIVE: To review the clinicopathologic features and MIB-1 labeling indices (marker of cell proliferation) of 14 subependymomas. DESIGN: Retrospective review of 14 subependymomas encountered in a tertiary care setting. RESULTS: Fourteen ependymomas presenting in 8 men and 6 women between the ages of 18 and 78 years (mean, 53.6 years) comprise the study group. The most common clinical presentations included ataxia (n = 4), dizziness/vertigo (n = 3), nausea/vomiting (n = 3), headaches (n = 3), and incidental finding at autopsy (n = 2). Tumor locations included fourth ventricle (n = 7), lateral ventricle (n = 4), third ventricle (n = 2), and thoracic spinal cord (n = 1). Eight patients underwent gross total resection, and 4 had subtotal resection. Tumors were characterized by clustering of cell nuclei arranged against a fibrillary background. Focal cystic degeneration was seen in 10 tumors, hemosiderin deposition in 8 tumors, sclerotic vessels in 8 tumors, calcifications in 5 tumors, and focal nuclear pleomorphism in 2 tumors. Mitotic figures, vascular endothelial proliferation, and necrosis were not seen in any of these tumors. Cell proliferation marker MIB-1 labeling indices (percentage of positive staining tumor cells) ranged from 0 to 1.4 (mean, 0.3). In comparison, 13 myxopapillary ependymomas had labeling indices ranging from 0 to 5.5 (mean, 1.1). Thirty-nine low-grade ependymomas had MIB-1 labeling indices of 0.1 to 5.4 (mean, 1.1). Fourteen anaplastic/malignant ependymomas had MIB-1 labeling indices ranging from 0.4 to 34.0 (mean, 12.8). One subependymoma was treated with radiation therapy. Six patients were alive with no evidence of tumor at a mean follow-up of 94.4 months. Two patients were alive with residual tumor (follow-up of 4 and 53 months). Two patients died with tumor at 0.67 and 43.4 months. One patient was lost to follow-up, 1 is a recent case, and 2 were incidental findings at autopsy. None of the patients developed tumor recurrence. CONCLUSIONS: Subependymomas are generally low-grade lesions, as evidenced by their benign clinical course and low MIB-1 labeling indices. Compared with other ependymal tumors, subependymomas have the lowest rate of cell proliferation as evidenced by MIB-1 immunostaining.
Subject(s)
Cerebral Ventricle Neoplasms/pathology , Glioma, Subependymal/pathology , Nuclear Proteins , Adult , Aged , Antigens, Nuclear , Cerebral Ventricle Neoplasms/physiopathology , Female , Glioma, Subependymal/physiopathology , Humans , Immunohistochemistry , Ki-67 Antigen , Male , Middle Aged , PrognosisABSTRACT
Spinal cord subependymoma is a rare tumour with only 39 reported cases in the literature. The authors report a further case of this neoplasm in a 53 year old man with a progressive paraparesis, paraesthesias of the lower limbs and sphincter disturbance. The tumour was partly removed, without progression 5 years after surgery. After a careful review of the literature, the optimal treatment of this spinal tumour is debated.
Subject(s)
Glioma, Subependymal/pathology , Spinal Cord Neoplasms/pathology , Glioma, Subependymal/physiopathology , Glioma, Subependymal/surgery , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Recovery of Function/physiology , Spinal Cord Neoplasms/physiopathology , Spinal Cord Neoplasms/surgery , Thoracic Vertebrae , Treatment OutcomeSubject(s)
Cerebral Ventricle Neoplasms/diagnostic imaging , Cerebral Ventricles/diagnostic imaging , Glioma, Subependymal/diagnostic imaging , Tremor/diagnostic imaging , Adult , Cerebral Ventricle Neoplasms/physiopathology , Cerebral Ventricle Neoplasms/surgery , Cerebral Ventricles/surgery , Cough/diagnostic imaging , Cough/physiopathology , Diagnosis, Differential , Female , Glioma, Subependymal/physiopathology , Glioma, Subependymal/surgery , Humans , Tremor/physiopathologyABSTRACT
A 62-year-old woman presented with a rare case of subependymoma associated with prominent Rosenthal fibers located in the left lateral ventricle manifesting as right hemiparesis and mild motor aphasia. The tumor was well demarcated and consisted of clusters of round nuclei embedded in an abundant gliofibrillary matrix with some microcysts and prominent Rosenthal fibers. Immunohistochemically, the tumor stained positively for glial fibrillary acidic protein and negatively for synaptophysin. This case of subependymoma containing Rosenthal fiber formation is very unusual.
Subject(s)
Astrocytes/pathology , Extracellular Matrix/pathology , Glioma, Subependymal/pathology , Lateral Ventricles/pathology , Cerebral Ventricle Neoplasms/pathology , Cerebral Ventricle Neoplasms/physiopathology , Cerebral Ventricle Neoplasms/surgery , Female , Glioma, Subependymal/physiopathology , Glioma, Subependymal/surgery , Humans , Lateral Ventricles/diagnostic imaging , Lateral Ventricles/surgery , Middle Aged , RadiographyABSTRACT
The authors present a 21-year-old woman who has been receiving rapamycin for 5 months for bilateral subependymal giant cell astrocytomas. The patient was started at a dose of 0.2 mg/kg/day. Levels were maintained between 11 and 13 ng/mL. Magnetic resonance imaging of the brain 2(1/2) months after initiating rapamycin demonstrated a decrease in size of both astrocytomas (11 to 7.5 mm on the right and 8 to 5 mm on the left). Further studies are needed with prolonged observation to confirm these findings, determine the length of necessary treatment, and evaluate recurrence risk after discontinuation of rapamycin.